论文部分内容阅读
主动脉瓣狭窄(Aortic Stenosis,AS)可见于先天性心脏病如二叶式主动脉瓣、风湿性心脏病或罕见的代谢病如褐黄病,但随着全球进入人口老龄化,AS主要见于老年人退行性心脏瓣膜疾病,在大于65岁的老年人中AS和AS前期主动脉瓣硬化分别达到3%和25%。AS是一种慢性进展性疾病,大多数病变终末期即有严重症状的患者需寻求主动脉瓣置换,显著增加老年人的死亡率。但是AS患者早期无症状或没有手术指征,有没有药物能够阻断或延缓疾病的进展?理论上,抗炎和抗增殖药物均有期望改变AS的
Aortic Stenosis (AS) can be seen in congenital heart disease such as bicuspid aortic valve, rheumatic heart disease or rare metabolic diseases such as brown disease, but as the global population ages, AS mainly occurs in In elderly patients with degenerative heart valve disease, 3% and 25% of aortic valve scoliosis occurs pre-AS and AS, respectively, in older adults than 65 years of age. AS is a chronic, progressive disease that requires the search for aortic valve replacement in most patients with terminal symptoms of severe disease, significantly increasing the mortality rate in the elderly. However, AS patients with asymptomatic early or no surgical indications, there is no drug can block or delay the progress of the disease? Theoretically, anti-inflammatory and anti-proliferative drugs are expected to change the AS